Letrozole for PCOS: How It Works and Why It's First-Line

You were handed a prescription for letrozole, probably with the words "we'll start with 2.5mg on days 3 to 7." You may also be holding a box that says Femara on it, recognise the name as a breast cancer drug, and feel a flicker of confusion. The aim of this post is to walk you through what letrozole is doing inside a polycystic ovary, why it became the default for ovulation induction in PCOS after 2014, and what your first cycle is likely to look like.

When I sit with someone new to medicated cycles, the first thing I want them to know is that letrozole is one of the most studied and best understood drugs we use in fertility medicine. It is inexpensive, it is taken as a short course of pills, and for people with polycystic ovary syndrome (PCOS) it consistently outperforms the older first-line drug, clomiphene citrate. That last point is not opinion. It was settled in a landmark New England Journal of Medicine trial published in 2014, and it has shaped how reproductive endocrinologists prescribe ever since.

Why is letrozole now first-line for PCOS?

For a long time, clomiphene was the standard. It worked, but not as well as we hoped, especially for people with PCOS. In 2014, Richard Legro and colleagues published the PALO trial in the New England Journal of Medicine: 750 women with PCOS, randomised to either letrozole or clomiphene for up to five treatment cycles.¹ The cumulative live-birth rate was 27.5% on letrozole versus 19.1% on clomiphene. The ovulation rate per cycle was 61.7% on letrozole versus 48.3% on clomiphene. Multiple pregnancies were similar, slightly favouring letrozole.

That gap, an eight-percentage-point advantage in live birth, is large for a fertility trial. It is the reason the American Society for Reproductive Medicine (ASRM), the National Institute for Health and Care Excellence (NICE), the European Society of Human Reproduction and Embryology (ESHRE), and the 2023 International Evidence-Based Guideline for PCOS all now recommend letrozole as the first-line ovulation induction drug for people with PCOS.⁶ The 2018 Cochrane review on aromatase inhibitors in PCOS reached the same conclusion: letrozole improves live-birth rates compared with clomiphene, with no signal of harm.³

There is another reason I almost always start with letrozole for PCOS, and it is mechanistic. Clomiphene blocks oestrogen receptors throughout the body, including at the endometrium, which is why some people on clomid develop a thin uterine lining. Letrozole works upstream by briefly lowering oestrogen production itself, and the drug clears the body before the fertile window. The lining is not exposed to the drug at the moment the embryo would implant. In a PCOS ovary, which already has a difficult relationship with the FSH:LH ratio, this matters.

There is also a quieter cost-and-access argument that I find worth naming. Letrozole is cheap. Generic 2.5mg pills are often $20 to $50 for a five-day course in the United States, and frequently free or near-free under most international health systems. It is taken orally, not injected. It does not require refrigeration. For a couple trying to conceive without unlimited resources, that combination, a drug that works better and costs less and is easier to administer, is unusual in medicine.

How does letrozole work for ovulation?

Letrozole is an aromatase inhibitor. Aromatase is the enzyme that converts androgens (testosterone, androstenedione) into oestrogens (oestradiol, oestrone). When you take a 2.5mg pill, you briefly block that conversion. Circulating oestrogen drops for a window of roughly 24 to 96 hours.

The brain interprets a drop in oestrogen as a signal that ovaries need pushing. The pituitary gland responds by releasing more follicle-stimulating hormone (FSH). That extra FSH pulse recruits an antral follicle in the ovary, the follicle starts producing its own oestrogen as it grows, and once that oestrogen rises, the normal feedback loop reasserts itself. The brain stops shouting, the follicle continues to mature, and ovulation follows somewhere around day 12 to 16 of the cycle.

Letrozole has a half-life of about 45 hours.⁴ A five-day course taken on cycle days 3 to 7 is essentially cleared from the bloodstream by the time ovulation happens. This is why letrozole does not thin the endometrial lining the way clomid sometimes does. By the time the follicle is mature and the lining is preparing for an embryo, the drug is gone.

If you have ever wondered why a drug used in oncology ended up in a fertility clinic, the answer is exactly this side of the molecule. Aromatase inhibitors were developed to lower oestrogen in oestrogen-receptor-positive breast cancer. Reproductive endocrinologists noticed the same brief oestrogen drop could be used to nudge an anovulatory ovary into ovulating, without the receptor-blocking baggage of clomid.⁴

The earliest off-label use of letrozole for ovulation induction was published by Mitwally and Casper at the start of the 2000s, in patients who had not responded to clomiphene. The signal they reported, ovulation in patients who had been classified clomid-resistant, prompted a decade of comparative studies that culminated in PALO. So when people search for how letrozole works expecting a simple answer, the honest version has three layers: a 24 to 96 hour oestrogen dip, a stronger pituitary FSH pulse, and a follicle that gets nudged across the selection threshold it could not cross on its own.

Why do PCOS ovaries respond differently to letrozole?

A non-PCOS ovary, in any given cycle, selects one antral follicle to mature and ovulate. That selection happens because of a delicate FSH:LH balance, and because individual follicles compete for the FSH pulse.

In PCOS, several things make selection harder:

• LH tends to run higher relative to FSH, so the FSH pulse the brain produces is often not strong enough.
• Insulin resistance, which sits underneath most PCOS, raises androgen production from the ovaries and the adrenal glands.
• Anti-Mullerian hormone (AMH) is often elevated, reflecting many small antral follicles waiting in line, none of which gets picked.
• Local follicular environments are oestrogen-rich, which paradoxically suppresses FSH further.

What a short course of letrozole does is produce a slightly stronger, slightly later FSH pulse than the PCOS ovary would generate on its own. That nudge is often enough to push one follicle past the selection threshold so it grows into a dominant follicle and ovulates. Crucially, it usually pushes only one or two follicles past that threshold, which is why the multiples rate stays manageable.

This is also why metformin is sometimes added alongside letrozole in PCOS. Metformin works on the insulin-resistance side of the equation, and there is some evidence that combining it with letrozole improves ovulation rates in patients who respond poorly to letrozole alone.⁶ I cover metformin in a separate post.

There is one more PCOS-specific consideration worth naming. Some people with PCOS have anti-Mullerian hormone (AMH) levels well above the normal range, sometimes two or three times higher. High AMH reflects the large pool of small antral follicles that PCOS ovaries carry, and it correlates with how vigorously the ovary will respond to FSH. A patient with very high AMH may produce more recruited follicles per cycle on letrozole than a patient with a typical AMH, which is part of why your RE will set cycle cancellation criteria (often three or four mature follicles) before any trigger is given.

What is the standard letrozole protocol?

The protocol most clinics use looks like this. Your reproductive endocrinologist (RE) may adjust it, and there are good reasons to do so, but this is the baseline.

1. Day 1: First day of a true period (not spotting). If you do not get a period spontaneously, your clinic may prescribe a short course of progesterone to induce a withdrawal bleed, then start the next step on day 3 of that bleed.
2. Days 3 to 7: Take 2.5mg of letrozole once a day, for five days. Some clinics use days 2 to 6 or days 5 to 9; the evidence for one window over another is modest. What matters is that you take it for five consecutive days.
3. Day 11 to 14: Transvaginal ultrasound scan to check follicle size and endometrial lining. Your RE is looking for at least one follicle reaching 18 to 22mm and a lining of about 7 to 12mm.
4. Trigger shot (optional): When the follicle is mature, some clinics give a single hCG injection to trigger ovulation at a known time, usually 24 to 36 hours later.
5. Timed intercourse or IUI: 24 to 36 hours after the trigger, or based on a positive ovulation predictor kit (OPK) if no trigger is used.
6. Day 21 (or 7 days post-ovulation): Progesterone blood test to confirm ovulation actually happened. A level above 10 ng/mL is generally reassuring.

If you are wondering when you will ovulate on letrozole days 3 to 7, the honest answer is "usually around day 12 to 16, but a scan tells you with far more precision than a calendar." I cover scan-day decisions in the follicle-tracking post.

What outcomes can I expect from letrozole cycle 1?

I want to be honest about cycle 1 because most people are not prepared for the gap between "I took the medication" and "I got pregnant." Here is what the PALO trial and the broader literature suggest you can expect.¹, ³

• Ovulation rate per cycle on 2.5mg: approximately 60% in PCOS.
• Pregnancy rate per cycle: roughly 17% to 22% when there are no other infertility factors.
• Cumulative live-birth rate over five cycles: 27.5% in PALO.
• Roughly 70% to 80% of pregnancies on letrozole happen within the first three ovulatory cycles.

Two things follow from those numbers. First, a negative test after cycle 1 does not mean letrozole "didn't work." Most people who eventually conceive on letrozole need a few cycles. Second, if you ovulate but do not conceive, that is meaningful data: it tells your RE the drug is doing its job, and the next conversation is about timing, sperm, lining, or tubes, not the dose.

I usually counsel patients to plan, mentally, for three to four cycles before re-evaluating. That is not a prediction. It is a way to protect your nervous system from treating cycle 1 as a referendum on the next decade of your life.

The same numbers also explain why most reproductive endocrinologists cap oral ovulation induction at four to six cycles before stepping up. Past that, the cumulative gain per additional letrozole cycle drops. If you have ovulated reliably for four cycles without a pregnancy, the conversation usually shifts to whether something other than ovulation is the limiting step: sperm parameters, tubal patency, endometrial lining, or simply the precision of timing that timed intercourse cannot provide.

Is letrozole safe, and what about the old controversy?

In the United States, letrozole is FDA-approved for early breast cancer. Its use in fertility is off-label, which means it has not been formally approved for that indication, but is widely prescribed because the evidence supports it. Off-label use is legal, common in fertility medicine, and not a sign of an experimental drug. Most of the medications used in fertility clinics worldwide are prescribed off-label.

There is one piece of history worth naming because patients still encounter it on older forums. In 2005, an abstract presented at the ASRM annual meeting suggested a possible increase in birth defects in babies conceived after letrozole. That abstract was not a peer-reviewed publication, and the manufacturer briefly added a contraindication to its label. Larger follow-up studies, particularly Tulandi et al. in 2006 (911 newborns), found no increased risk of congenital malformations on letrozole compared with clomiphene.⁵ Subsequent research and large meta-analyses have not detected a signal.

ACOG, ASRM, NICE, ESHRE, and the 2023 International PCOS Guideline all currently endorse letrozole for ovulation induction in PCOS.⁶ If you read something online suggesting otherwise, it is almost certainly drawing on the 2005 abstract.

I want to be specific about what "first-line" actually means in current guideline language, because the phrase gets used loosely. The 2023 International Evidence-Based Guideline for PCOS states that letrozole should be considered the first pharmacological treatment for ovulation induction in anovulatory infertility in PCOS, in preference to clomiphene, when there are no contraindications.⁶ That is a strong recommendation supported by the evidence base. It is the operating standard in most fertility clinics worldwide.

What are the side effects of letrozole?

Most letrozole side effects are short, mild, and traceable to the oestrogen dip during the dosing window. The common ones are fatigue, hot flashes or night sweats, headache, dizziness, and occasional nausea. They tend to peak between days 3 and 6 and ease by ovulation. I cover the full list, and the three symptoms that warrant a same-day call to the clinic, in a dedicated side-effects post.

What letrozole does not typically do, despite Reddit lore: it does not thin the lining, it does not cause hair loss in standard five-day cycles, it does not cause long-term ovarian damage, and it does not raise lifetime cancer risk at fertility doses.

The reason I keep flagging the difference between fertility doses and oncology doses is that almost every "long-term side effect" search result will pull from the breast cancer literature, where letrozole is taken daily for years and the cumulative exposure is many multiples higher than a five-day fertility course. Those side effects (bone density changes, joint pain, cardiovascular effects) are not relevant to a course of three or four fertility cycles. If your search history is full of letrozole side effects after 5 years results, you are reading studies of women on chronic letrozole for breast cancer prevention, not ovulation induction.

What should I ask my doctor about letrozole?

Before the cycle starts, or before cycle 2 if you are reading this after a negative test, these are the conversations worth having with your RE.

• Why this starting dose, and what is the plan if I do not ovulate.
• Will we do a follicle scan this cycle, and on which day.
• Am I a candidate for adding metformin given my insulin profile.
• What is the cancel criterion if too many follicles develop.
• How many cycles at the current step before we change protocol.

If you have a partner involved in this with you, this is also the conversation where it helps to align on what "stepping up" would mean later, because that decision is easier in the calm before the cycle than in the disappointment of a negative test.

What's next

• If your first letrozole cycle ends in a positive test: the two-week wait
• If your first cycle ended in a negative test and you're heading into cycle 2: what changes between cycles
• If you have completed three or more cycles without success: when letrozole didn't work or moving up to IUI
• If this cycle failed and you need support before the next decision: Section 11, when things don't go to plan

Related in this cluster

• Letrozole Side Effects: What's Normal, What to Call About
• Letrozole Dose: 2.5mg, 5mg, 7.5mg and What Determines Yours
• Letrozole Success Rates: By Age, PCOS Status, and Cycle Count

Sources

1. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2014;371(2):119-129. https://www.nejm.org/doi/full/10.1056/NEJMoa1313517
2. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertility and Sterility 2013;100(2):341-348. https://www.asrm.org/practice-guidance/practice-committee-documents/
3. Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2018;(5):CD010287. https://doi.org/10.1002/14651858.CD010287.pub3
4. Casper RF, Mitwally MFM. A historical perspective of aromatase inhibitors for ovulation induction. Fertility and Sterility 2012;98(6):1352-1355. https://doi.org/10.1016/j.fertnstert.2012.10.008
5. Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertility and Sterility 2006;85(6):1761-1765. https://doi.org/10.1016/j.fertnstert.2006.03.014
6. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025